Oxford Immunotec Global PLC (OXFD) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a hold rating to a sell rating in a research report report published on Tuesday.

OXFD has been the topic of a number of other research reports. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a hold rating to a sell rating in a research report on Wednesday, August 30th. Cowen and Company reissued a buy rating and set a $19.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. BTIG Research initiated coverage on Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They set a buy rating and a $21.00 price target on the stock. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $19.75.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at $13.25 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.51 and a current ratio of 4.72.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The business had revenue of $26.10 million for the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. The firm’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.29) earnings per share. research analysts anticipate that Oxford Immunotec Global PLC will post -2.11 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Oxford Immunotec Global PLC (OXFD) Stock Rating Lowered by ValuEngine” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/04/oxford-immunotec-global-plc-oxfd-stock-rating-lowered-by-valuengine.html.

In related news, COO Peter Edwardson sold 22,371 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $17.70, for a total transaction of $395,966.70. Following the sale, the chief operating officer now owns 102,644 shares of the company’s stock, valued at approximately $1,816,798.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,110 shares of company stock worth $1,563,564. Company insiders own 8.11% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Birchview Capital LP boosted its holdings in shares of Oxford Immunotec Global PLC by 14.9% during the 3rd quarter. Birchview Capital LP now owns 77,303 shares of the company’s stock valued at $1,299,000 after acquiring an additional 10,000 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in shares of Oxford Immunotec Global PLC by 34.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 423,831 shares of the company’s stock valued at $7,129,000 after acquiring an additional 108,154 shares in the last quarter. Asymmetry Capital Management L.P. acquired a new stake in shares of Oxford Immunotec Global PLC during the 2nd quarter valued at $273,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Oxford Immunotec Global PLC by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Redmile Group LLC boosted its holdings in shares of Oxford Immunotec Global PLC by 7.5% during the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock valued at $36,263,000 after acquiring an additional 151,100 shares in the last quarter. 79.21% of the stock is currently owned by institutional investors.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit